Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine , 2025; 392 (16): 1569 DOI: 10.1056/NEJMoa2411664 Cite This Page : ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of ...

Most bronchiectasis patients experience loss of lung function over time due to the irreversible damage caused by the progressive disease. But in this large, international, randomized ASPEN trial ...

“This scheme targets patients aged 18 or above who have been diagnosed with asthma, bronchiectasis or chronic obstructive pulmonary disease, and experience persistent respiratory symptoms ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma Itepekimab expanding into chronic ...

Finally, itepekimab is being explored in a phase 2 study in bronchiectasis, with the readout anticipated in 2026. In May 2024, Sanofi reported results from the Phase 2 study of oral rilzabrutinib ...

He was 88. He was also affected by a "previous episode of acute respiratory failure in bilateral multimicrobial pneumonia, multiple bronchiectasis, arterial hypertension and type II diabetes ...